Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Armstrong Discusses ARCHES Trial in Prostate Cancer

March 1st 2019

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

Pre-existing Cardiovascular Disease Linked to Higher Mortality With Abiraterone

February 28th 2019

Pre-existing cardiovascular disease was associated with an increased mortality risk during the first 6 months of abiraterone acetate treatment in patients with advanced prostate cancer.

FDA Approval Sought for Darolutamide for Nonmetastatic CRPC

February 27th 2019

A new drug application has been filed with the FDA for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer. ​

Dr. Concepcion on Potential for Immunotherapy in CRPC

February 27th 2019

Raoul S. Concepcion, MD, FACP, director, Comprehensive Prostate Center, discusses the potential for immunotherapy in the treatment of patients with castration-resistant prostate cancer.

Dr. Slovin Discusses Risk Factors for ADT-Associated Cardiac Complications in Prostate Cancer

February 26th 2019

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses risk factors for androgen deprivation therapy (ADT)-associated cardiac complications in prostate cancer.

Dr. Yu Discusses Treatment Strategies for Patients With Oligometastatic Prostate Cancer

February 23rd 2019

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment strategies for patients with oligometastatic prostate cancer.

Expert Highlights Nivolumab/Ipilimumab Potential in mCRPC

February 23rd 2019

Sumit K. Subudhi, MD, PhD, discusses the promise of the combination of nivolumab and ipilimumab in patients with metastatic castration-resistant prostate cancer and the challenges that lie ahead with this treatment approach.

SM-88 Safe, Active in Nonmetastatic CRPC

February 22nd 2019

Benjamin A. Gartrell, MD, discusses the promise of SM-88 in this patient population, as well as other therapeutic options that are emerging for various prostate cancer subtypes.

Dr. Subudhi Discusses Rationale for CheckMate-650 Study in Prostate Cancer

February 21st 2019

Sumit K. Subudhi, MD, PhD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the rationale for the CheckMate-650 study in the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Rayford on the Racial Genomics of Prostate Cancer

February 19th 2019

Walter Rayford, MD, PhD, MBA, a urologic oncologist with the Urology Group and associate professor of medicine at the University of Tennessee West Cancer Center, discusses the racial genomics of prostate cancer.

Dr. Ranganath on Treatment Considerations in Nonmetastatic Prostate Cancer

February 19th 2019

Harsha Ranganath, MD, a fellow in the Division of Hematology & Oncology at the University of Tennessee West Cancer Center, discusses treatment considerations in nonmetastatic prostate cancer.

The Challenge of Precision Medicine in mCRPC

February 18th 2019

It may take a restructuring of our current practice models, but we need to embrace, understand, and incorporate new technologies, both surgical and nonsurgical, to be at the forefront of precision medicine for our patients.

PARP Inhibitors Hold Promise in mCRPC and Biallelic DNA Repair Gene Defects

February 18th 2019

Evan Y. Yu, MD, highlights 2 key studies with PARP inhibitors in metastatic castration-resistant prostate cancer and discussed challenges that need to be addressed in this space in order to further progress.

Dr. Desai on MRI Imaging for Bone Metastases in CRPC

February 16th 2019

Arpita Desai, MD, medical oncologist, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the rationale for testing MRI functional imaging for bone metastases in men with castration-resistant prostate cancer.

Layered Treatment With Radium-223 and Abiraterone May Reduce Skeletal Events in mCRPC

February 16th 2019

In a real-world setting, patients with metastatic castration-resistant prostate cancer who received radium-223 dichloride with abiraterone acetate in a layered fashion experienced a lower rate of symptomatic skeletal events compared with those who received the treatments concurrently.

Enzalutamide Extends Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

February 16th 2019

The addition of enzalutamide (Xtandi) to androgen deprivation therapy significantly prolonged radiographic progression-free survival compared with ADT alone in men with metastatic hormone-sensitive prostate cancer.

Darolutamide Improves Metastasis-Free Survival in Nonmetastatic CRPC

February 16th 2019

Darolutamide added to androgen deprivation therapy significantly improved metastasis-free survival compared with placebo plus ADT in patients with nonmetastatic castration-resistant prostate cancer enrolled in the phase III ARAMIS trial.

Hereditary Prostate Cancer—What Urologists Should Know

February 15th 2019

Historically, urologists have been the primary caretakers for men with localized prostate cancer, which is the most prevalent solid tumor in men over 50 years of age and the second-leading cause of cancer-specific mortality in the United States today.

Finasteride Safe and Effective in Prostate Cancer Prevention

February 15th 2019

The 5α-reductase inhibitor finasteride (Proscar), an agent commonly used to treat lower urinary tract problems and baldness in men, was found to be safe and effective in reducing the risk of prostate cancer.

Dr. George on Sequential Therapy in Metastatic Prostate Cancer

February 15th 2019

Daniel J. George, MD, professor of Medicine and Surgery, member, Duke Cancer Institute, discusses sequential therapy in metastatic prostate cancer.

NEXT PAGE
PREVIOUS PAGE